LivaNova

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $1.47 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.15 billion, down 6.3% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.10 billion, up 100% from a year earlier.SEC EDGAR filings (XBRL)
• Latest earnings call or results release (August 5, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
• Guidance in the last 90 days: 2 outlook figures raised, 1 lowered, 0 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed February 25, 2026): 3 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $0.8 million on the open market.SEC Form 4
• 303 institutional managers reported a position at June 30, 2026 (+11 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 4 (6 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for LivaNova yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (FOLEY & LARDNER LLP)third_quarter 2026 · $0.1 million
2. Oct 20, 2026Lobbying
   Lobbying report (LIVANOVA USA, INC.)third_quarter 2026 · $0.2 million
3. Oct 16, 2026Lobbying
   Lobbying report (JEFFREY J. KIMBELL AND ASSOCIATES)third_quarter 2026 · $0.0 million
4. Oct 6, 2026Patent
   Patent granted: OXYGENATOR WITH IMPROVED BLOOD MIXINGUS 12752044
5. Sep 1, 2026Patent
   Patent granted: SYSTEMS AND METHODS FOR HEART VALVE THERAPYUS 12721726
6. Aug 11, 2026Patent
   Patent granted: MODULAR HEATER COOLER WITH DISPOSABLE HEAT TRANSFER FLUID CIRCUITUS 12702735
7. Aug 4, 2026Patent
   Patent granted: DUAL LUMEN CANNULA WITH ADJUSTABLE LENGTH INFUSION TUBEUS 12697468
8. Jul 21, 2026Patent
   Patent granted: DIMENSIONALLY ADJUSTABLE EXTRACORPOREAL LIFE SUPPORT CANNULAUS 12685858
9. Jul 20, 2026Lobbying
   Lobbying report (LIVANOVA USA, INC.)second_quarter 2026 · $0.2 million
10. Jul 20, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)second_quarter 2026 · $0.0 million
11. Jul 19, 2026Lobbying
    Lobbying report (FOLEY & LARDNER LLP)second_quarter 2026 · $0.1 million
12. Jun 11, 20268-K
    Shareholder vote resultsItem 5.07
13. Apr 20, 2026Lobbying
    Lobbying report (JEFFREY J. KIMBELL & ASSOCIATES, INC.)first_quarter 2026 · $0.0 million
14. Apr 20, 2026Lobbying
    Lobbying report (FOLEY & LARDNER LLP)first_quarter 2026 · $0.1 million
15. Feb 25, 202610-K
    Annual report (10-K)3 risk factors added, 1 removed
16. Jan 14, 20268-K
    Director or officer changeItem 5.02
17. Sep 4, 20258-K
    Director or officer changeItem 5.02
18. Jun 11, 20258-K
    Director or officer changeItem 5.02
19. Jun 11, 20258-K
    Shareholder vote resultsItem 5.07
20. Feb 25, 202510-K
    Annual report (10-K)2 risk factors added, 3 removed
21. Feb 29, 202410-K
    Annual report (10-K)2 risk factors added, 5 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1639691